197 related articles for article (PubMed ID: 26456754)
1. Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer.
Arnold SA; Loomans HA; Ketova T; Andl CD; Clark PE; Zijlstra A
Clin Exp Metastasis; 2016 Jan; 33(1):29-44. PubMed ID: 26456754
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis.
Dong F; Shen Y; Xu T; Wang X; Gao F; Zhong S; Chen S; Shen Z
World J Surg Oncol; 2018 Mar; 16(1):61. PubMed ID: 29562940
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
[TBL] [Abstract][Full Text] [Related]
4. Structural alterations of sugar chains in urine fibronectin from bladder cancer patients and its enzymatic mechanism.
Guo JM; Zhang XY; Chen HL; Wang GM; Zhang YK
J Cancer Res Clin Oncol; 2001 Aug; 127(8):512-9. PubMed ID: 11501752
[TBL] [Abstract][Full Text] [Related]
5. Fetal fibronectin: a new screening-marker for bladder cancer?
Wunderlich H; Reichelt O; Zermann DH; Schubert J; Berndt A; Kosmehl H
Oncol Rep; 2001; 8(3):669-72. PubMed ID: 11295100
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
7. The clinical relevance of urine-based markers for diagnosis of bladder cancer.
Eissa S; Swellam M; Amin A; Balbaa ME; Yacout GA; El-Zayat TM
Med Oncol; 2011 Jun; 28(2):513-8. PubMed ID: 21437743
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
Eissa S; Zohny SF; Zekri AR; El-Zayat TM; Maher AM
Med Oncol; 2010 Dec; 27(4):1286-94. PubMed ID: 20012564
[TBL] [Abstract][Full Text] [Related]
9. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic potential of urinary α1-antitrypsin and apolipoprotein E in the detection of bladder cancer.
Urquidi V; Goodison S; Ross S; Chang M; Dai Y; Rosser CJ
J Urol; 2012 Dec; 188(6):2377-83. PubMed ID: 23088986
[TBL] [Abstract][Full Text] [Related]
11. Urinary protein biomarker panel for the detection of recurrent bladder cancer.
Rosser CJ; Chang M; Dai Y; Ross S; Mengual L; Alcaraz A; Goodison S
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1340-5. PubMed ID: 24714076
[TBL] [Abstract][Full Text] [Related]
12. IL-8 as a urinary biomarker for the detection of bladder cancer.
Urquidi V; Chang M; Dai Y; Kim J; Wolfson ED; Goodison S; Rosser CJ
BMC Urol; 2012 May; 12():12. PubMed ID: 22559832
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
14. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer.
Arnold Egloff SA; Du L; Loomans HA; Starchenko A; Su PF; Ketova T; Knoll PB; Wang J; Haddad AQ; Fadare O; Cates JM; Lotan Y; Shyr Y; Clark PE; Zijlstra A
Oncotarget; 2017 Jan; 8(1):722-741. PubMed ID: 27894096
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder.
Yan Y; Yang FQ; Zhang HM; Li J; Li W; Wang GC; Che JP; Zheng JH; Liu M
Int J Clin Exp Pathol; 2014; 7(7):4231-8. PubMed ID: 25120803
[TBL] [Abstract][Full Text] [Related]
16. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
McNeil BK; Sorbellini M; Grubb RL; Apolo A; Cecchi F; Athauda G; Cohen B; Giubellino A; Simpson H; Agarwal PK; Coleman J; Getzenberg RH; Netto GJ; Shih J; Linehan WM; Pinto PA; Bottaro DP
J Transl Med; 2014 Oct; 12():199. PubMed ID: 25335552
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.
Urquidi V; Goodison S; Kim J; Chang M; Dai Y; Rosser CJ
Urology; 2012 May; 79(5):1185.e1-6. PubMed ID: 22386755
[TBL] [Abstract][Full Text] [Related]
18. IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).
Richter P; Junker K; Franz M; Berndt A; Geyer C; Gajda M; Kosmehl H; Berndt A; Wunderlich H
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1059-65. PubMed ID: 18386055
[TBL] [Abstract][Full Text] [Related]
19. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
20. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
